The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Search for "drug pricing"

Search results for: drug pricing

Florida Law Puts Drug Pricing by Pharmacy Benefit Managers Under a Microscope Once Again

August 8, 2022 • By Catherine Kolonko

As of July 1, a Florida bill increases oversight of pharmacy benefit managers and offers some protection for pharmacies. However, the legislation has limited effects on patients and providers, highlighting the need for additional reform.... [Read More]

Filed Under: Legislation & Advocacy Tagged With: Florida, pharmacy benefit managers (PBMs), state legislation

RheumPAC Donors Discuss Healthcare Legislation, Drug Pricing with Rep. Lloyd Doggett

May 7, 2021 • By Zach Wallace, MD, MSc

At a virtual event with the chair of the Ways & Means Subcommittee on Health, RheumPAC donors were able to share concerns and recommendations about drug pricing policies and how they affect providers and patients.... [Read More]

Filed Under: American College of Rheumatology, Legislation & Advocacy Tagged With: Legislation & Advocacy, Lloyd Doggett, RheumPAC

Drug Pricing Bills Move Forward

September 20, 2019 • By Angus Worthing, MD, FACP, FACR

This week, the U.S. House of Representatives released a long-anticipated plan that contains provisions to reduce U.S. drug prices according to an international price index.... [Read More]

Filed Under: Drug Updates Tagged With: drug pricing, Legislation

Making Sense of Drug Pricing Legislation

July 2, 2019 • By From the College

A number of bills have been introduced in the 116th Congress to mitigate the impact of treatment and drug costs on U.S. patients. The ACR has reviewed the bills and supports those that most closely align with its positions on access to care.... [Read More]

Filed Under: Drug Updates, Legislation & Advocacy, Professional Topics Tagged With: Advocacy, American College of Rheumatology, drug, Legislation, rheumatology

WHO Drug Pricing Talks May Fail to End Secrecy, Activists Fear

May 26, 2019 • By Tom Miles

GENEVA (Reuters)—Governments are working on a drug pricing transparency deal at the World Health Organization’s (WHO) annual assembly, but activists said on Thursday they fear crucial costs may be left out, enabling pharmaceutical firms to keep prices high. Campaigners say some drugs are exhorbitantly priced, even though they are often developed with public funding, and… [Read More]

Filed Under: Drug Updates, Pharma Co. News Tagged With: drug pricing transparency, drug pricing transparency deal, pharmaceutical industry, World Health Organization (WHO)

U.S. Lawmaker Launches Investigation into Pharma Drug Pricing

January 15, 2019 • By Yasmeen Abutaleb

WASHINGTON (Reuters)—A top U.S. lawmaker has launched an investigation into pharmaceutical industry pricing practices, less than a week after he and fellow Democrats introduced legislation aimed at lowering medicine prices. Rep. Elijah Cummings (D-Md.), who chairs the U.S. House Oversight Committee, sent letters to 12 drug makers seeking information on price increases, investment in research… [Read More]

Filed Under: Drug Updates Tagged With: costs, drug cost, drug cost legislation, U.S. Congressional Budget Office

ACR Responds to Drug Pricing Proposals

June 21, 2018 • By Mary Beth Nierengarten

Responding to the Trump administration’s drug pricing proposals, the ACR released a set of principles it hopes will help guide any drug policy changes.1 The principles underscore what is critically needed for rheumatologists to provide the best and safest care to their patients, many of whom require ongoing treatment for chronic conditions. “The ACR has… [Read More]

Filed Under: Legislation & Advocacy, Professional Topics Tagged With: ACR principles, American Patients First Drug Pricing Blueprint, drug policy changes, Trump administration’s drug pricing proposals

ACR/ARHP Visits the Hill; Drug Pricing ‘Blueprint’ Revealed

June 8, 2018 • By Angus Worthing

Greetings, Advocates! In my last update, I described the great news from February’s budget agreement that fixed Medicare’s payment adjustments so MIPS penalties would not include Part B drug costs, ensuring stabilization of the Medicare Part B drug system, among other successes. (Read the ACR’s press release on this topic.) I also described the Trump administration’s… [Read More]

Filed Under: American College of Rheumatology, Legislation & Advocacy Tagged With: Angus update, Association of Rheumatology Professionals (ARP), Biosimilars, blueprint, drug prices, fly-in, Washington D.C. update

ACR Leads Coalition Response to HHS Proposed Drug Pricing Threats

April 20, 2018 • By Carina Stanton

Potential federal drug pricing proposals could shuffle Part B drug coverage into the Part D program and restructure reimbursements for new drugs, moves that would jeopardize patient access to care, explains Kent “Kwas” Huston, MD, a rheumatologist in Kansas City, Mo., and a member of the ACR’s Government Affairs Committee (GAC). “We believe Part D… [Read More]

Filed Under: Legislation & Advocacy Tagged With: ACR coalition, coalition response, HHS, Kent “Kwas” Huston, Part B drug coverage, proposed drug pricing threats, restructure reimbursements

FDA’s Gottlieb Blames Industry ‘Kabuki Drug Pricing’ for High Costs

March 8, 2018 • By Yasmeen Abutaleb

WASHINGTON (Reuters)—U.S. Food and Drug Administration chief, Scott Gottlieb, criticized pharmacy benefit managers, health insurers and drugmakers on Wednesday for “Kabuki drug-pricing constructs” that profit the industry at the expense of consumers. The comments, made at a conference organized by a leading U.S. health insurer lobbying group, stoked speculation over what steps the administration of… [Read More]

Filed Under: Drug Updates, Professional Topics Tagged With: drugmakers, FDA Commissioner Scott Gottlieb, Kabuki drug-pricing constructs, pharmacy benefit managers, U.S. Food and Drug Administration chief, U.S. health insurers

  • 1
  • 2
  • 3
  • …
  • 18
  • Next Page »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)